title: Simultaneous immunohistochemical detection of IUdR and BrdU infused intravenously to cancer patients.
abstract: Cell cycle kinetics of solid tumors in the past have been restricted to an in vitro labeling index (LI) measurement. Two thymidine analogues, bromodeoxyuridine (BrdU) and iododeoxyuridine (IUdR), can be used to label S-phase cells in vivo because they can be detected in situ by use of monoclonal antibodies (MAb) against BrdU (Br-3) or IUdR (3D9). Patients with a variety of solid tumors (lymphoma, brain, colon cancers) received sequential intravenous IUdR and BrdU. Tumor tissue removed at the end of infusion was embedded in plastic and treated with MAb Br-3 and 3D9 sequentially, using a modification of a previously described method. Clearly single and double labeled cells were visible, which enabled us to determine the duration of S-phase (Ts) and the total cell cycle time (Tc), in addition to the LI in these tumors. Detailed control experiments using tissue culture cell lines as well as bone marrow cells from leukemic patients are described, including the comparison of this double label technique with our previously described BrdU-tritiated thymidine technique. We conclude that the two methods are comparable and that the IUdR/BrdU method permits rapid and reliable cell cycle measurements in solid tumors.
authors.affiliation: Barrett Cancer Center, University of Cincinnati Medical Center, Ohio 45267.
authors.forename: M A
authors.initials: MA
authors.lastname: Miller
authors.forename: C M
authors.initials: CM
authors.lastname: Mazewski
authors.forename: N
authors.initials: N
authors.lastname: Yousuf
authors.forename: Y
authors.initials: Y
authors.lastname: Sheikh
authors.forename: L M
authors.initials: LM
authors.lastname: White
authors.forename: G A
authors.initials: GA
authors.lastname: Yanik
authors.forename: D M
authors.initials: DM
authors.lastname: Hyams
authors.forename: B C
authors.initials: BC
authors.lastname: Lampkin
authors.forename: A
authors.initials: A
authors.lastname: Raza
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D001973:Bromodeoxyuridine / Q000008:administration & dosage / Q000276:immunology / Q000378:metabolism*; D002453:Cell Cycle / Q000502:physiology; D003110:Colonic Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007065:Idoxuridine / Q000008:administration & dosage / Q000276:immunology / Q000378:metabolism*; D007150:Immunohistochemistry / Q000379:methods*; D007262:Infusions, Intravenous; D007938:Leukemia / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D008223:Lymphoma / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D010865:Pilot Projects; D016196:S Phase / Q000502:physiology; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D001973:Bromodeoxyuridine; D007065:Idoxuridine